2.10

1.45% 0.03

Alx Oncology Holdings Inc (ALXO)

Overview News Price History Option Chain Financials Discussions Forecast

Alx Oncology Holdings Inc stock is traded at $2.10, with a volume of 765.31K. It is up +1.45% in the last 24 hours and up +44.83% over the past month. ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Previous Close:

$2.07

Open:

$2.04

24h Volume:

765.31K

Relative Volume:

0.56

Market Cap:

$282.58M

Revenue:

Net Income/Loss:

$-101.70M

P/E Ratio:

-1.1075

EPS:

-1.8961

Net Cash Flow:

$-84.35M

1W Performance:

-1.18%

1M Performance:

+44.83%

6M Performance:

+79.49%

1Y Performance:

+326.83%

1-Day Range:

$1.985

$2.16

1-Week Range:

$1.90

$2.16

52-Week Range:

$0.444

$2.66

Alx Oncology Holdings Inc Stock (ALXO) Company Profile

Name

Alx Oncology Holdings Inc

Sector

Healthcare (1092)

Industry

Biotechnology (603)

Phone

650-466-7125

Address

323 ALLERTON AVENUE, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

ALXO's Discussions on Twitter

Compare ALXO vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALXO Alx Oncology Holdings Inc	2.10	278.55M	0	-101.70M	-84.35M	-1.8961
VRTX Vertex Pharmaceuticals Inc	485.65	123.36B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.69	71.18B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	860.55	53.68B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	186.16	38.09B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	267.47	37.80B	4.29B	577.22M	641.34M	4.2086

Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-19-26	Initiated	Wells Fargo	Overweight
Mar-06-26	Resumed	UBS	Buy
Nov-13-25	Initiated	Jefferies	Buy
Mar-06-25	Upgrade	Jefferies	Hold → Buy
Dec-19-24	Downgrade	Jefferies	Buy → Hold
Mar-08-24	Downgrade	Stifel	Buy → Hold
Dec-08-23	Upgrade	Jefferies	Hold → Buy
Dec-22-21	Downgrade	Jefferies	Buy → Hold
Sep-30-21	Initiated	Stifel	Buy
May-05-21	Resumed	Credit Suisse	Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Apr-06-21	Initiated	UBS	Buy
Feb-10-21	Initiated	H.C. Wainwright	Buy
Aug-11-20	Initiated	Cantor Fitzgerald	Overweight
Aug-11-20	Initiated	Credit Suisse	Outperform
Aug-11-20	Initiated	Jefferies	Buy
Aug-11-20	Initiated	Piper Sandler	Overweight

View All

Alx Oncology Holdings Inc Stock (ALXO) Latest News

Jul 09, 2026

BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell? - The Globe and Mail

Jul 09, 2026

Jul 08, 2026

ALXO Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineEstimate Uncertainty - dars.gov.et

Jul 08, 2026

Jul 06, 2026

ALX Oncology (ALXO) SVP sells 1,404 shares for RSU tax obligations - Stock Titan

Jul 06, 2026

Jul 05, 2026

ALXOAlx Oncology Holdings Inc Options - Finviz

Jul 05, 2026

Jul 02, 2026

ALX Oncology (ALXO) Edges Higher as Biotech Sector Shows Selective InterestLast Point Support - DonanımHaber

Jul 02, 2026

Jun 30, 2026

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - The Manila Times

Jun 30, 2026

Leadership shifts at ALX Oncology (NASDAQ: ALXO) as Garland becomes chair - Stock Titan

Jun 30, 2026

ALX Oncology names Scott Garland chairman, adds general counsel - Investing.com UK

Jun 30, 2026

ALX Oncology names Scott Garland chairman, adds general counsel By Investing.com - Investing.com India

Jun 30, 2026

ALXO Welcomes New Leadership with Board Changes - GuruFocus

Jun 30, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 30, 2026

ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel - Investing News Network

Jun 30, 2026

ALX Oncology appoints Scott Garland as chairman and Michael Listgarten as general counsel to strengthen leadership - Traders Union

Jun 30, 2026

Jun 29, 2026

ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026